Zobrazeno 1 - 10
of 77
pro vyhledávání: '"KEISUKE YOKOHAMA"'
Autor:
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Takeshi Hatanaka, Joji Tani, Koichi Takaguchi, Masanori Atsukawa, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Kazuto Tajiri, Toru Ishikawa, Satoshi Yasuda, Hidenori Toyoda, Shinya Fukunishi, Chikara Ogawa, Satoru Kakizaki, Noritomo Shimada, Atsushi Naganuma, Kazuhito Kawata, Hisashi Kosaka, Hidekatsu Kuroda, Tomomitsu Matono, Yutaka Yata, Hironori Ochi, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Keisuke Yokohama, Hiroki Nishikawa, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Takashi Kumada, Representing the Real‐life Practice Experts for HCC Study Group with Hepatocellular Carcinoma experts from 48 clinics in Japan (RELPEC/HCC 48 Group)
Publikováno v:
Cancer Reports, Vol 7, Iss 4, Pp n/a-n/a (2024)
Abstract Aims The aim of the present study was to elucidate detailed parameters for prediction of prognosis for patients with unresectable hepatocellular carcinoma (uHCC) receiving atezolizumab plus bevacizumab (Atez/Bev) treatment. Methods A total o
Externí odkaz:
https://doaj.org/article/db2c34e45940412fa92f5beffa4e949a
Autor:
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Keisuke Yokohama, Hiroki Nishikawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Atsushi Naganuma, Yutaka Yata, Hideko Ohama, Hidekatsu Kuroda, Kazunari Tanaka, Takaaki Tanaka, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, the Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publikováno v:
Cancer Medicine, Vol 12, Iss 24, Pp 21680-21693 (2023)
Abstract Aim This retrospective study compared the impact of atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib (LEN) on the liver function in patients with hepatocellular carcinoma. Methods We included 526 patients who received Atez/Bev and 731
Externí odkaz:
https://doaj.org/article/47d83858206f4fedb8133cae3683b6fd
Autor:
Masahiro Matsui, Akira Asai, Kosuke Ushiro, Saori Onishi, Tomohiro Nishikawa, Keisuke Yokohama, Hideko Ohama, Yusuke Tsuchimoto, Soo Ki Kim, Hiroki Nishikawa
Publikováno v:
Diagnostics, Vol 13, Iss 11, p 1959 (2023)
SARC-F is a well-accepted screening tool for sarcopenia. A SARC-F value of 1 point is reported to be more discriminating in identifying sarcopenia than 4 points (recommended cutoff point). The prognostic impact of the SARC-F score was investigated in
Externí odkaz:
https://doaj.org/article/bf072235c00f4926b262cee10e4c88d2
Autor:
Yoshihiro Inoue, Yusuke Suzuki, Keisuke Yokohama, Hideko Ohama, Yusuke Tsuchimoto, Akira Asai, Shinya Fukunishi, Fumiharu Kimura, Kazuhide Higuchi, Kazuhisa Uchiyama
Publikováno v:
Contemporary Oncology, Vol 24, Iss 4, Pp 211-215 (2021)
Externí odkaz:
https://doaj.org/article/d941fd5228394db684798ebcce0d112f
Autor:
Yoshihiro Inoue, Masatsugu Ishii, Keisuke Yokohama, Hideko Ohama, Yusuke Tsuchimoto, Tetsuji Terazawa, Akira Asai, Shinya Fukunishi, Kazuhide Higuchi, Kazuhisa Uchiyama
Publikováno v:
Contemporary Oncology, Vol 24, Iss 3, Pp 172-176 (2020)
Externí odkaz:
https://doaj.org/article/5bde1f44e15040948f57aa6b0baccda7
Autor:
Abeer Hassan, Yasuhiro Tsuda, Akira Asai, Keisuke Yokohama, Ken Nakamura, Tetsuya Sujishi, Hideko Ohama, Yusuke Tsuchimoto, Shinya Fukunishi, Usama M. Abdelaal, Usama A. Arafa, Ali T. Hassan, Ali M. Kassem, Kazuhide Higuchi
Publikováno v:
Mediators of Inflammation, Vol 2015 (2015)
Transarterial chemoembolization (TACE) is usually followed by hepatic dysfunction. We evaluated the effects of L-carnitine on post-TACE impaired liver functions. Methods. 53 cirrhotic hepatocellular carcinoma patients at Osaka Medical College were en
Externí odkaz:
https://doaj.org/article/1f2bb20cd01c4641af4eb60121e8b913
Autor:
Suzune Sugishima, Hideko Ohama, Hiroki Nishikawa, Hidetaka Yasuoka, Keisuke Yokohama, Kosuke Ushiro, Masahiro Matsui, Tomohiro Nishikawa, Yusuke Tsuchimoto, Akira Asai, Shinya Fukunishi, Yasuhiro Tsuda, Kazuhide Higuchi
Publikováno v:
Kanzo. 63:456-462
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eba88913b12f5425e43e785123083c60
https://doi.org/10.2957/kanzo.63.456
https://doi.org/10.2957/kanzo.63.456
Autor:
Hideko Ohama, Hiroki Nishikawa, Kosuke Ushiro, Masahiro Matsui, Tomohiro Nishikawa, Ken Nakamura, Keisuke Yokohama, Yusuke Tsuchimoto, Akira Asai, Shinya Fukunishi, Atsushi Takeshita, Yasuhiro Tsuda, Kazuhide Higuchi
Publikováno v:
Kanzo. 63:381-387
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bd0b6004cebbfd1ce797a8bc3127512
https://doi.org/10.2957/kanzo.63.381
https://doi.org/10.2957/kanzo.63.381
Autor:
Nishikawa, Masahiro Matsui, Akira Asai, Kosuke Ushiro, Saori Onishi, Tomohiro Nishikawa, Keisuke Yokohama, Hideko Ohama, Yusuke Tsuchimoto, Soo Ki Kim, Hiroki
Publikováno v:
Diagnostics; Volume 13; Issue 11; Pages: 1959
SARC-F is a well-accepted screening tool for sarcopenia. A SARC-F value of 1 point is reported to be more discriminating in identifying sarcopenia than 4 points (recommended cutoff point). The prognostic impact of the SARC-F score was investigated in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::9eac7f5ec1866ddf6a958f1f74687488
Autor:
MASAHIRO MATSUI, AKIRA ASAI, KOSUKE USHIRO, KEISUKE YOKOHAMA, SHINYA FUKUNISHI, SOO KI KIM, HIROKI NISHIKAWA
Publikováno v:
In Vivo
Aim: To elucidate factors contributing to hepatitis B virus (HBV)-DNA clearance following tenofovir alafenamide (TAF) therapy in nucleoside analogue (NA) naïve patients with chronic hepatitis B (CHB) (n=92, 11 cirrhotic cases). Patients and Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e2390cad42e896db86d1efb28955365
https://europepmc.org/articles/PMC10026686/
https://europepmc.org/articles/PMC10026686/
